Our preliminary results indicate that while the addition of CpG may induce a mild increase in the number of CD40 - B cells generated we have not identified any significant increase in expression of
B cell surface molecules over and above a negative GpC control.
Not exact matches
Blincyto (blinatumomab) is designed to treat cancers expressing a
molecule called CD19 — found on the
surface of
B cell ALL and also non-Hodgkin's lymphoma.
CD20 is a
B - lymphocyte
surface molecule that is widely expressed during
B -
cell ontogeny, from early pre-
B-
cell developmental stages until final differentiation into plasma
cells.
A significant percentage of children and young adults with treatment - resistant
B -
cell leukemia achieved remission through a new CAR T -
cell gene therapy that destroys cancer
cells with the CD22
molecule on its
surface.